News | January 12, 2022
Covaxin booster neutralises Omicron and Delta variants: Study
The study will be published on the pre-print server, medRXiv, shortly
The study will be published on the pre-print server, medRXiv, shortly
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
The brand is now available pan-India through their distribution partner
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
It plans to deliver over 300 million doses to the Indian government
Subscribe To Our Newsletter & Stay Updated
